

Daxdilimab

| | |
|-----------|---|
| Cat. No.: | HY-P99226 |
| CAS No.: | 2245966-28-1 |
| Target: | SARS-CoV |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

Description

Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research^{[1][2]}.

REFERENCES

[1]. Patel S, et al. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon. 2021 Feb;7(2):e06158.

[2]. Retamozo S, et al. An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opin Pharmacother. 2021 Dec;22(17):2359-2371.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA